SIETES :: 91969 citas

Resultados de la búsqueda por REVISIÓN SISTEMÁTICA REFINAR BÚSQUEDA

1.

Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S, Benedetto U. Tolerability of new antiepileptic drugs: a network meta-analysis. Eur J Clin Pharmacol 2017;73:811-7. [Ref.ID 101994]

2.

de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol 2017;73:517-23. [Ref.ID 101992]

3.

Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]

4.

Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266. [Ref.ID 101981]

5.

Driessen JHM, de Vries F, van Onzenoort H, Harvey NC, Neef C, van den Bergh JPW, Vestergaard P, Henry RMA. The use of incretins and fractures – A meta-analysis on population-based real life data. Br J Clin Pharmacol 2017;83:923-6. [Ref.ID 101971]

6.

Mahr A, Golmard C, Pham E, Iordache L, Deville L, Faure P. Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials. Pharmacoepidemiol Drug Saf 2017;26:731-41. [Ref.ID 101966]

7.

Walsh EK, Hansen CR, Sahm LJ, Kearney PM, Doherty E, Bradley CP. Economic impact of medication error: a systematic review. Pharmacoepidemiol Drug Saf 2017;26:481-97. [Ref.ID 101957]

8.

Lee SWH, Chaiyakunapruk N, Lai NM. What G6PD-deficient individuals should really avoid. Br J Clin Pharmacol 2017;83:211-2. [Ref.ID 101931]

9.

Lee SWH, Lai NM, Chaiyakunapruk N, Chong DWK. Adverse effects of herbal or dietary supplements in G6PD deficiency: a systematic review. Br J Clin Pharmacol 2017;83:172-9. [Ref.ID 101929]

10.

Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol 2017;73:927-35. [Ref.ID 101927]

11.

da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2017;390:8 de julio. [Ref.ID 101669]

12.

Hawkes N. Are new hepatitis C drugs all they’re cracked up to be?. BMJ 2017;357:j2961. [Ref.ID 101659]

13.

Mezzacappa A, Lasica P-A, Gianfagna F. Risk of autism spectrum disorders according to period of prenatal antidepressant exposure. A systematic review and meta-analysis. JAMA Pediatrics 2017;171:555-63. [Ref.ID 101641]

14.

Manhapra A, Rosenheck R. Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. BMJ 2017;357:j1947. [Ref.ID 101635]

15.

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550. [Ref.ID 101634]

16.

Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, Li S, Guyatt GH, Sun X. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 2017;357:j2499. [Ref.ID 101630]

17.

Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]

18.

Tsai W-C, Wu H-Y, Peng Y-S, Yang J-Y, Chen HY, Chiu Y-L, Hsu S-P, Ko M-J, Pai M-F, Tu Y-K, Hung K-Y, Chien K-L. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med 2017;177:792-9. [Ref.ID 101619]

19.

Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med 2017;177:784-91. [Ref.ID 101618]

20.

Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, Rojas-Fernández C, Walsh K, Welch V, Moayyedi P. Deprescribing proton pump inhibitors. Evidence-based clinical practice guideline. Canadian Family Physician - Le Médecin de Famille Canadien 2017;63:354-64. [Ref.ID 101592]